Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study
(2023)
Journal Article
Grove, J. I., Stephens, C., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A., …on behalf of the TransBioLine consortium. (2023). Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study. Diagnostic and Prognostic Research, 7, Article 18. https://doi.org/10.1186/s41512-023-00155-z
A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium compri... Read More about Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study.